AION Diagnostics is a global research-based imaging company whose vision is to enhance the delivery of care through early detection and diagnosis of disease. Our focus is on prevention rather than cure.

AION is committed to commercialization of products that enhance current medical imaging, allowing timely intervention before symptoms arise.

As medical imaging systems rapidly evolve to include combination imaging techniques in a single scan, there is a new emerging demand for hybrid imaging agents.

Traditionally different materials, each visible on a different modality, have provided the clinician with the ability to provide the contrast required for imaging an ultrasound, X-ray, CT, PET or MRI. Today, the ability to provide contrast with a "one-stop-shop" contrast agent is being realized.

Based on a novel discovery made by QinetiQ, formerly the UK Government Defense Evaluation & Research Agency (DERA), AION has created a unique imaging platform with the ability to be visualized on key imaging modalities in a single formulation. AION has advanced the platform to multi-modality applications in:

• Marking Agents
• Hybrid Contrast Agents
• Next-generation Hybrid Molecular Imaging Agents